Lee's Pharmaceutical Holdings Limited (0950.HK)
HKD 1.37
(-0.72%)
HKD 1.37
(-0.72%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.05 Billion HKD | -14.61% |
| 2022 | 1.23 Billion HKD | -2.61% |
| 2021 | 1.26 Billion HKD | 4.06% |
| 2020 | 1.21 Billion HKD | -0.18% |
| 2019 | 1.21 Billion HKD | 7.15% |
| 2018 | 1.13 Billion HKD | 12.8% |
| 2017 | 1 Billion HKD | 8.46% |
| 2016 | 929.82 Million HKD | 0.83% |
| 2015 | 922.15 Million HKD | -3.46% |
| 2014 | 955.2 Million HKD | 37.05% |
| 2013 | 696.95 Million HKD | 30.43% |
| 2012 | 534.33 Million HKD | 33.69% |
| 2011 | 399.68 Million HKD | 56.24% |
| 2010 | 255.81 Million HKD | 47.16% |
| 2009 | 173.83 Million HKD | 38.6% |
| 2008 | 125.42 Million HKD | 63.5% |
| 2007 | 76.71 Million HKD | 76.22% |
| 2006 | 43.53 Million HKD | 12.99% |
| 2005 | 38.52 Million HKD | 26.76% |
| 2004 | 30.39 Million HKD | 64.32% |
| 2003 | 18.49 Million HKD | 58.86% |
| 2002 | 11.64 Million HKD | 12.55% |
| 2001 | 10.34 Million HKD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q4 | 270.36 Million HKD | 0.0% |
| 2023 Q2 | 256.15 Million HKD | 0.0% |
| 2023 Q1 | 256.15 Million HKD | 30.05% |
| 2023 FY | 1.05 Billion HKD | -14.61% |
| 2023 Q3 | 270.36 Million HKD | 5.55% |
| 2022 Q4 | 196.96 Million HKD | -49.11% |
| 2022 Q1 | 324.75 Million HKD | 3.5% |
| 2022 Q2 | 324.41 Million HKD | -0.1% |
| 2022 Q3 | 387.01 Million HKD | 19.3% |
| 2022 FY | 1.23 Billion HKD | -2.61% |
| 2021 Q2 | 300.91 Million HKD | 6.28% |
| 2021 Q4 | 313.77 Million HKD | -14.81% |
| 2021 FY | 1.26 Billion HKD | 4.06% |
| 2021 Q3 | 368.33 Million HKD | 22.41% |
| 2021 Q1 | 283.14 Million HKD | -12.25% |
| 2020 FY | 1.21 Billion HKD | -0.18% |
| 2020 Q1 | 272.98 Million HKD | -10.51% |
| 2020 Q2 | 283.73 Million HKD | 3.94% |
| 2020 Q3 | 337.32 Million HKD | 18.89% |
| 2020 Q4 | 322.67 Million HKD | -4.34% |
| 2019 FY | 1.21 Billion HKD | 7.15% |
| 2019 Q3 | 306.33 Million HKD | -5.63% |
| 2019 Q4 | 305.04 Million HKD | -0.42% |
| 2019 Q1 | 282.94 Million HKD | 4.52% |
| 2019 Q2 | 324.59 Million HKD | 14.72% |
| 2018 Q4 | 270.7 Million HKD | -9.53% |
| 2018 Q2 | 285.81 Million HKD | 1.39% |
| 2018 Q1 | 281.9 Million HKD | 8.94% |
| 2018 FY | 1.13 Billion HKD | 12.8% |
| 2018 Q3 | 299.2 Million HKD | 4.68% |
| 2017 Q2 | 248.55 Million HKD | 9.88% |
| 2017 Q1 | 226.2 Million HKD | -2.15% |
| 2017 FY | 1 Billion HKD | 8.46% |
| 2017 Q3 | 275.01 Million HKD | 10.65% |
| 2017 Q4 | 258.76 Million HKD | -5.91% |
| 2016 Q4 | 231.16 Million HKD | -7.13% |
| 2016 Q3 | 248.92 Million HKD | 11.03% |
| 2016 Q1 | 225.53 Million HKD | 6.39% |
| 2016 Q2 | 224.19 Million HKD | -0.6% |
| 2016 FY | 929.82 Million HKD | 0.83% |
| 2015 FY | 922.15 Million HKD | -3.46% |
| 2015 Q3 | 232.26 Million HKD | -6.19% |
| 2015 Q2 | 247.58 Million HKD | 7.49% |
| 2015 Q1 | 230.32 Million HKD | -13.35% |
| 2015 Q4 | 211.98 Million HKD | -8.73% |
| 2014 Q2 | 236.5 Million HKD | 14.69% |
| 2014 Q3 | 246.67 Million HKD | 4.3% |
| 2014 Q4 | 265.81 Million HKD | 7.76% |
| 2014 FY | 955.2 Million HKD | 37.05% |
| 2014 Q1 | 206.21 Million HKD | 11.6% |
| 2013 Q2 | 186.32 Million HKD | 25.51% |
| 2013 Q3 | 177.4 Million HKD | -4.78% |
| 2013 Q4 | 184.77 Million HKD | 4.15% |
| 2013 FY | 696.95 Million HKD | 30.43% |
| 2013 Q1 | 148.44 Million HKD | 1.54% |
| 2012 FY | 534.33 Million HKD | 33.69% |
| 2012 Q3 | 132.36 Million HKD | -9.27% |
| 2012 Q1 | 109.88 Million HKD | -15.25% |
| 2012 Q2 | 145.89 Million HKD | 32.76% |
| 2012 Q4 | 146.19 Million HKD | 10.45% |
| 2011 Q1 | 73.67 Million HKD | 0.0% |
| 2011 Q4 | 129.66 Million HKD | 23.01% |
| 2011 FY | 399.68 Million HKD | 56.24% |
| 2011 Q2 | 90.94 Million HKD | 23.43% |
| 2011 Q3 | 105.4 Million HKD | 15.9% |
| 2010 FY | 255.81 Million HKD | 47.16% |
| 2010 Q2 | 60.67 Million HKD | 0.0% |
| 2009 Q2 | 43.57 Million HKD | 0.0% |
| 2009 FY | 173.83 Million HKD | 38.6% |
| 2008 FY | 125.42 Million HKD | 63.5% |
| 2007 FY | 76.71 Million HKD | 76.22% |
| 2006 FY | 43.53 Million HKD | 12.99% |
| 2005 FY | 38.52 Million HKD | 26.76% |
| 2004 FY | 30.39 Million HKD | 64.32% |
| 2003 FY | 18.49 Million HKD | 58.86% |
| 2002 FY | 11.64 Million HKD | 12.55% |
| 2001 FY | 10.34 Million HKD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -306.329% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 89.999% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -1681.844% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -34.336% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | -9.544% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 38.295% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -30.148% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -158.82% |
| SSY Group Limited | 6.46 Billion HKD | 83.707% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -62.401% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 28.258% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.611% |